Bret Jensen, Seeking Alpha

Bret Jensen

Seeking Alpha

Miami Beach, FL, United States

Contact Bret

Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.

Start free trial

  • Seeking Alpha
  • TheStreet

Recent articles by Bret:

If It Looks Like A Duck, And Quacks Like A Duck

The bottom line is there is a recession on the horizon and investors should prepare for that reality regardless of how it is currently being spun. → Read More

Dynavax Technologies Delivers (NASDAQ:DVAX)

Dynavax Technologies continues to gain market share with its Hepatitis B vaccine and is seeing revenue growth from Covid-19 efforts. Read more about DVAX here. → Read More

3 Bold Market Predictions For Summer

Stocks bounced back in July after the worst first six months to open a new year in a half-century. Read more to see 3 bold market predictions. → Read More

Arrowhead Pharmaceuticals: An RNAi Name To Know (NASDAQ:ARWR)

Shares of RNA interference concern Arrowhead Pharmaceuticals are down over 50% since making an all-time high in June 2021. Read more about ARWR stock here. → Read More

Fulgent Genetics: Poised To Survive Its Post-Covid Hangover (NASDAQ:FLGT)

Fulgent Genetics benefitted greatly from an explosion of Covid-19 testing revenue. Read more for an investment analysis on the FLGT stock. → Read More

BioCryst Pharmaceuticals: Waiting For Clarity (NASDAQ:BCRX)

Shares of BioCryst are down some 40% since announcing a voluntary halt to 3 trials involving its BCX9930 program on April 8, 2022. Click here for a full investment analysis. → Read More

Sizing Up SpringWorks Therapeutics Stock (NASDAQ:SWTX)

Today, we put SpringWorks Therapeutics in the spotlight. Its lead asset looks headed for its first NDA filing. Read more for an analysis of SWTX. → Read More

Ocugen Stock: Prudent Play Is To Avoid At This Time (NASDAQ:OCGN)

Ocugen (OCGN) has several early-stage gene therapies. Click here to know why I think that the prudent play is to avoid OCGN stock at this time. → Read More

Veracyte Stock: Fading The Rally (NASDAQ:VCYT)

Veracyte shares have shot up approximately 60% over the past month, snapping a deep decline. Read more to find out why Veracyte’s narrative is enticing. → Read More

Geron Stock: Waiting For Godot (NASDAQ:GERN)

Today, we revisit a small biopharma called Geron for the first time since early in 2021. Read more for an investment analysis on the GERN stock. → Read More

Circling Back On Agile Therapeutics Stock (NASDAQ:AGRX)

Today, we revisit a small biopharma called Agile Therapeutics for the first time in a year and a half. See an analysis of AGRX stock here. → Read More

Checking Out Chinook Therapeutics Stock (NASDAQ:KDNY)

Chinook Therapeutics has reacted well recently to a surprising secondary offering conducted at $14.00. Read what to know about KDNY stock here. → Read More

Evofem Biosciences Stock: An Evaluation (NASDAQ:EVFM)

Today, we take a deeper look at a birth control biopharma concern called Evofem Biosciences, Inc. whose shares have plummeted to a buck a piece. Read more here. → Read More

3 Bold Predictions For The Second Half Of 2022

Stocks just had one of their worst starts to a year in history. What will the second half of 2022 bring? Click here to know our three bold predictions. → Read More

Nothing Compelling About Natera Stock (NASDAQ:NTRA)

Shares of diagnostic testing concern Natera are down 70% from their all-time high set in September 2021. Read about NTRA stock here. → Read More

IVERIC bio Stock: A First Take (NASDAQ:ISEE)

IVERIC bio stock has seen some insider buying here in June and its primary asset Zumira seems on the path to commercialization. Read more on ISEE stock here. → Read More

ChemoCentryx Stock: Revisiting The Investment Case (NASDAQ:CCXI)

ChemoCentryx posted a Q1 GAAP loss of $.55 a share; both top & bottom line missed expectations. Why do I plan to hold my position in CCXI stock? Find out. → Read More

The Prognosis For Personalis Stock (NASDAQ:PSNL)

Personalis stock has taken a battering in 2022 & is posting substantial quarterly losses, but shares now sell for less than net cash. Read more on PSNL here. → Read More

Vaxart: A Unique Vaccine Concern (NASDAQ:VXRT)

Vaxart is developing several vaccine candidates targeting large potential markets via an oral pill that can be stored at room temperature. See more on VXRT here. → Read More

Collegium Pharmaceutical: Oversold And Cheap (NASDAQ:COLL)

With high leverage expected to deflate by YE22 and currently trading at three times FY22E EPS, Collegium (COLL) merited a deeper dive. See why I think COLL stock is a buy. → Read More